Immutep Expands Part B of TACTI-002 Study
March 05, 2021 08:00 ET
|
Immutep Limited
Sydney, AUSTRALIA, March 05, 2021 (GLOBE NEWSWIRE) -- – Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases,...
Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
March 04, 2021 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 04, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Pol Boudes,...
Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020
December 11, 2020 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes,...
Galectin Therapeutics Inc. Recaps Results of Annual Meeting of Stockholders Presentation
December 04, 2020 16:17 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the passing of the two...
Galectin Therapeutics to Webcast Corporate Update on December 3, 2020 after Annual Meeting of Stockholders
December 01, 2020 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that management will...
Immutep’s Phase II TACTI-002 Study Reports Encouraging Data at SITC
November 09, 2020 16:10 ET
|
Immutep Limited
Sydney, Australia, Nov. 10, 2020 (GLOBE NEWSWIRE) -- ASX/Media Release...
Galectin Therapeutics Provides Business Update And Reports Financial Results for the Quarter Ended September 30, 2020
November 09, 2020 08:00 ET
|
Galectin Therapeutics Inc.
Innovative Phase 2b/3 NASH-RX Trial in NASH Cirrhosis Initiated Board Member Joel Lewis Assumes CEO Role – Board Adds Two New Highly Accomplished Professionals NORCROSS, Ga., Nov. 09, 2020 ...
Correction: Non-Small Cell Lung Cancer Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade
November 06, 2020 02:34 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Non-Small Cell Lung Cancer Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade The Non-Small Cell Lung Cancer Pipeline...
Non-Small Cell Lung Cancer Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade
November 02, 2020 10:17 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Non-Small Cell Lung Cancer Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade The Non-Small Cell Lung Cancer Pipeline...
Galectin Therapeutics Investor Conference Call and Webinar Taking Place Today
September 29, 2020 12:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced that the Company will host...